NIBC acted as joint global coordinator and joint bookrunner in the successful rights offering of Vivoryon TherapeuticsNews Release -
NIBC is pleased to announce that Vivoryon Therapeutics AG has successfully completed a capital raise of approximately EUR 43 million via a rights offering to existing shareholders and a private placement to selected qualified investors in Europe. NIBC acted as joint global coordinator and joint bookrunner and supported the Company with all aspects of this important milestone.
The proceeds from the Offering will be used and are expected to be sufficient to fully finance the European Phase 2b clinical study with the Company’s lead product PQ912 for Alzheimer’s Disease, in particular for manufacturing the drug PQ912 and testing it in approximately 250 Alzheimer’s patients, and bringing it through to Phase 2b results in 2022. The remaining proceeds will be used to prepare and initiate the US Phase 2b clinical trial with PQ912.
Jean Paul Mannie, Director Equity Capital Markets commented: “We are happy that we were able to support Vivoryon in performing a successful capital raise via a rights issue to fund their Alzheimer’s Disease program. The deal demonstrates our ability to source and execute cross-border Equity Capital Markets transactions in the Life Sciences field, building on our international network and specialist expertise. We wish the Vivoryon team lots of success in developing a potential new drug for this important disease area.”